Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $49,904.10 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 12,322 shares of Checkpoint Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total value of $49,904.10. Following the completion of the transaction, the chief financial officer now directly owns 1,446,322 shares in the company, valued at $5,857,604.10. This represents a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

William Garrett Gray also recently made the following trade(s):

• On Thursday, February 6th, William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70.

Checkpoint Therapeutics Stock Performance

CKPT stock opened at $4.01 on Friday. The stock has a market cap of $195.82 million, a P/E ratio of -2.18 and a beta of 1.21. The firm has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $3.32. Checkpoint Therapeutics, Inc. has a 52 week low of $1.38 and a 52 week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.47). The business had revenue of $0.04 million for the quarter. Sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Checkpoint Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock valued at $1,425,000 after buying an additional 17,460 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Checkpoint Therapeutics by 226.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 425,000 shares of the company’s stock valued at $1,360,000 after acquiring an additional 295,000 shares during the last quarter. 683 Capital Management LLC bought a new stake in Checkpoint Therapeutics in the fourth quarter worth approximately $522,000. HB Wealth Management LLC increased its stake in shares of Checkpoint Therapeutics by 96.9% during the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after purchasing an additional 75,560 shares during the last quarter. Finally, PVG Asset Management Corp raised its holdings in shares of Checkpoint Therapeutics by 9.2% during the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after purchasing an additional 12,676 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Analyst Upgrades and Downgrades

CKPT has been the subject of several research analyst reports. HC Wainwright restated a “neutral” rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Lake Street Capital restated a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, D. Boral Capital reiterated a “buy” rating and set a $4.80 price target on shares of Checkpoint Therapeutics in a report on Monday, March 31st.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.